Mario Walther

Mario Walther

Auto-generated profile, based on publicly available information

Mario Walther

Department of Fundamental Sciences, Jena University of Applied Sciences, Jena, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Leukemia Research
Verified
Journal Article
Closed access
BGBernd Gruhn
Bernd Gruhn
Thomas NaumannThomas Naumann
Thomas Naumann
DGDorothee Gruner
Dorothee Gruner
MWMario Walther
Mario Walther
SWSusan Wittig
Susan Wittig
JSJürgen Sonnemann
Jürgen Sonnemann

22 June 2014 in NMR in Biomedicine
Verified
Journal Article
Closed access
PDF file
PHPatrick Hiepe
Patrick Hiepe
AGAlexander Gussew
Alexander Gussew
RRReinhard Rzanny
Reinhard Rzanny
CAChristoph Anders
Christoph Anders
MWMario Walther
Mario Walther
JRJürgen R. Reichenbach
Jürgen R. Reichenbach

27 May 2020 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
MRMaria Reckziegel
Maria Reckziegel
CWClaudia Weber-Osel
Claudia Weber-Osel
RERenate Egerer
Renate Egerer
BGBernd Gruhn
Bernd Gruhn
FKFlorian Kubek
Florian Kubek
AKAndi Krumbholz
Andi Krumbholz
Respiratory tract infections (RTI) can take a serious course under immunosuppression. Data on the impact of the underlying pathogens are still controversial. Samples from the upper (n = 322) and lower RT (n = 169) were collected from 136 children and 355 adults; 225 among them have been immunocompromised patients. Exclusion criteria were presence of relevant cultivable microorganisms, C-reactive protein > 20 mg/dl, or procalcitonin > 2.0 ng/ml. Samples were tested by PCR for the presence of herpesviruses (HSV-1/-2; VZV; CMV; HHV6; EBV), adenoviruses, bocaviruses, entero-/rhinoviruses (HRV), parechoviruses, coronaviruses, influenza viruses (IV), parainfluenza viruses as well as for pneumoviruses (HMPV and RSV), and atypical bacteria (Mycoplasma pneumoniae, M.p.; Chlamydia pneumoniae, C.p.). Viral/bacterial genome equivalents were detected in more than two-thirds of specimens. Under immunosuppression, herpesviruses (EBV 30.9%/14.6%, p < 0.001; CMV 19.6%/7.9%, p < 0.001; HSV-1: 14.2%/7.1%, p = 0.012) were frequently observed, mainly through their reactivation in adults. Immunocompromised adults tended to present a higher RSV prevalence (6.4%/2.4%, p = 0.078). Immunocompetent patients were more frequently tested positive for IV (15.0%/5.8%, p = 0.001) and M.p. (6.4%/0.4%, p < 0.001), probably biased due to the influenza pandemic of 2009 and an M.p. epidemic in 2011. About 41.8% of samples were positive for a single pathogen, and among them EBV (19.9%) was most prevalent followed by HRV (18.2%) and IV (16.6%). HSV-2 and C.p. were not found. Marked seasonal effects were observed for HRV, IV, and RSV. Differences in pathogen prevalence were demonstrated between immunocompetent and immunocompromised patients. The exact contribution of some herpesviruses to the development of RTI remains unclear.

17 June 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JKJosephine Krainhöfer
Josephine Krainhöfer
MWMario Walther
Mario Walther
MSMatthias Steinert
Matthias Steinert
ARAngelika Reissig
Angelika Reissig
Introduction. The aim of this retrospective study was to examine effect of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) in second-line and further therapy in daily clinical practice.Methods. Patients with histologically or cytologically proven NSCLC (n=84) treated with erlotinib in second-line (n=34), third-line (n=36), and more-line therapy (n=14) were examined for progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of therapy, and adverse effects.Results. Median PFS of all lines was 83 days (CI 70.0–96.0), OS was 7 months (CI 4.7–9.3), DCR was 66.2% (CI 55–77%), and 1-year survival rate was 33% (CI 22–43%), with no significant difference between therapy lines. Median duration of treatment was 76 days (IQR 39–139.5). Patients with epidermal growth factor receptor mutation (EGFR-M) reached the highest PFS (204 days), as did patients with good performance status (ECOG 0-1: 94 versus ECOG 2-3: 65 days,P=0.035). Patients with EGFR-M also revealed a DCR of 100%. The most frequent side effects were rash (69%) and diarrhoea (41%), without any significant difference between therapy lines. In 24 patients, the treatment dose was reduced and in 18, the therapy was paused.Conclusion. Erlotinib works in all therapy lines without any significant differences in efficacy and side effects.

28 October 2017
Verified
Book Chapter
Closed access
PDF file
JLJörn von Lucke
Jörn von Lucke
RHRoland Heuermann
Roland Heuermann
HPHelmut Poder
Helmut Poder
MWMario Walther
Mario Walther
HRHeinrich Rentmeister
Heinrich Rentmeister
MPMichael Pachmajer
Michael Pachmajer

1 December 2021 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
MRMaria Reckziegel
Maria Reckziegel
CWClaudia Weber-Osel
Claudia Weber-Osel
RERenate Egerer
Renate Egerer
BGBernd Gruhn
Bernd Gruhn
FKFlorian Kubek
Florian Kubek
AKAndi Krumbholz
Andi Krumbholz